Name: Latest research reports of Lupin Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Lupin Ltd.

NSE: LUPIN | BSE: 500257 | ISIN: INE326A01037 | Industry: Pharmaceuticals
| Mid-range Performer

2043.4000 55.40 (2.79%)

NSE Sep 12, 2025 15:54 PM

Volume: 1.6M

High volume today

Lupin Ltd.

09 Nov 2024

2043.40

2.79%

Lupin (BUY): In-line quarter; EBITDAM guidance increased to 25%

Buy: Lupin Ltd.

Recommendation Target

BOB Capital Markets Ltd.

LPC's earnings were in line with our estimates but beat street's estimates. EBITDA margin was 23% in Q2FY25

Lupin Ltd. has an average target of 2326.00 from 8 brokers.